Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

kevinmik Jan. 25 at 5:23 PM

$MNKD New Afrezza label hopefully announced tomorrow should be a huge catalyst. The new label is coming off of very positive results seen in the Inhale-3 study that utilized a higher initial conversion dose from mealtime injectable insulin to inhaled insulin. The new dosing scheduled establishes a titrated basal-bolus ratio that is approximately 70/30 inhaled insulin to basal vs. 50/50 for usual care. The results seen in the inhale-3 study using new dosing schedule were remarkable as seen with the 17 week results below and results from the extension phase showed that more people living with T1D are able to reach target A1c levels when they remain on Afrezza (plus basal insulin) or switch to Afrezza from usual care – whether they are using multiple daily injections or pumps. I hope the press release announcing FDA approval for new lable will also include a conference call to be held to revisit these excellent resutls and impact on sales. 17 week resuts:

1 · Reply

grampslol Jan. 25 at 3:42 PM

Goog morning $MNKD

0 · Reply

rooksleanne Jan. 25 at 3:38 PM

$MNKD Good Morning ☕🤗

0 · Reply

clan Jan. 25 at 12:34 PM

$MNKD Would you be less likely to hold shares, and believe positively, in the future of this company, if no ID was required to vote on the annual shareholders' meeting's agenda items? Like exec. compensation, ... $NVDA $AAPL

1 · Reply

grampslol Jan. 25 at 12:27 PM

$MNKD Afizzle scripts wk ending 1/16/26 New 328 Refills 477 #worldwideflop

0 · Reply

An_atom_is_a_hot_sok Jan. 25 at 8:12 AM

$MNKD https://www.facebook.com/watch/?v=1157221392938610

0 · Reply

An_atom_is_a_hot_sok Jan. 25 at 8:10 AM

$MNKD

0 · Reply

clan Jan. 25 at 4:31 AM

$MNKD up from here ↗️ $SPY

0 · Reply

RockyRambo25 Jan. 25 at 4:26 AM

$MNKD I think the PR was held back to bring us SOME GOOD MONDAY MORNING NEWS TO KICK OFF THE WEEK!!! Cheers!🍸

1 · Reply

kevinmik Jan. 25 at 2:28 AM

$MNKD Nice Comment James BrandtJames Brandt Dormitory Furniture Design Consultant at dba Brandt Design & EngineeringDormitory Furniture Design Consultant at dba Brandt Design & Engineering 4 days ago • Visible to anyone on or off LinkedIn The FDA’s upcoming January 23, 2026 decision on MannKind Corporation’s (MNKD) supplemental application for an Afrezza (insulin human) Inhalation Powder label update is poised to accelerate Afrezza adoption dramatically. This revision simplifies and increases the initial dose conversion for patients transitioning from injectable rapid‑acting insulin. By aligning dosing more closely with real‑world needs, it will help new users experience Afrezza’s benefits more quickly and more consistently. -Continued-

1 · Reply

MoneyShow's Best Investment Ideas For 2026: Part 5

HRL HUT IDXX IONQ KDK

Jan 12, 2026, 3:57 PM EST - 12 days ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

Jan 8, 2026, 8:05 AM EST - 17 days ago

MannKind Provides Business Updates and 2026 Growth Drivers

Dec 23, 2025, 8:05 AM EST - 4 weeks ago

MannKind Shares FUROSCIX® Business Updates

Dec 3, 2025, 11:46 AM EST - 7 weeks ago

MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients

Dec 1, 2025, 8:05 AM EST - 7 weeks ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Nov 11, 2025, 4:05 PM EST - 2 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 10, 2025, 1:21 PM EST - 2 months ago

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

Nov 10, 2025, 8:00 AM EST - 2 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 6, 2025, 9:00 AM EST - 2 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 5, 2025, 3:51 PM EST - 2 months ago

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 2 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 4:05 PM EDT - 3 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 15, 2025, 12:55 PM EDT - 3 months ago

MannKind: Durable Cash Engine, Optional Catalysts Pending

Oct 13, 2025, 8:05 AM EDT - 3 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 3 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 4 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 4 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 4 months ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 4 months ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 4 months ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 5 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 5 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 5 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 5 months ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 6 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 6 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 6 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 6 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 6 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 8 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 8 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 8 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 8 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 9 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 9 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 9 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 10 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 11 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 11 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 11 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 11 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 1 year ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 1 year ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 1 year ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 1 year ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 1 year ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

kevinmik Jan. 25 at 5:23 PM

1 · Reply

grampslol Jan. 25 at 3:42 PM

Goog morning $MNKD

0 · Reply

rooksleanne Jan. 25 at 3:38 PM

$MNKD Good Morning ☕🤗

0 · Reply

clan Jan. 25 at 12:34 PM

1 · Reply

grampslol Jan. 25 at 12:27 PM

$MNKD Afizzle scripts wk ending 1/16/26 New 328 Refills 477 #worldwideflop

0 · Reply

An_atom_is_a_hot_sok Jan. 25 at 8:12 AM

$MNKD https://www.facebook.com/watch/?v=1157221392938610

0 · Reply

An_atom_is_a_hot_sok Jan. 25 at 8:10 AM

$MNKD

0 · Reply

clan Jan. 25 at 4:31 AM

$MNKD up from here ↗️ $SPY

0 · Reply

RockyRambo25 Jan. 25 at 4:26 AM

$MNKD I think the PR was held back to bring us SOME GOOD MONDAY MORNING NEWS TO KICK OFF THE WEEK!!! Cheers!🍸

1 · Reply

kevinmik Jan. 25 at 2:28 AM

1 · Reply

RockyRambo25 Jan. 25 at 2:14 AM

$MNKD I am just a hard working individual who is investing my own money in hopes I can make some extra money to retire before I die. I don’t have any insider connections like many in Washington but I sure would like to be a fly on the wall in some of those elected officials homes. Can you imagine all the money you invested in Mannkind and it pops and you made 3500% profit in just a few years? I would be happy if we get a 10 bagger from this level over the next few years. Cheers!🍸

2 · Reply

Affizle Jan. 25 at 1:13 AM

$MNKD So dead just like Affizle? LOLZ!

1 · Reply

BenYiju Jan. 25 at 1:07 AM

$MNKD Company has a real product (unlike outright scams like $ORMP) but the CEO and his crony hires hijack all the profits in egregious compensation and keeping a high rent headquarters in Corruptofornia instead of where all of the company’s real work is done back in CT. Good product, bad investment, criminal management. 👎

1 · Reply

kevinmik Jan. 25 at 1:00 AM

$MNKD Afrezza Pediatric & Furoscix Autoinjector approvals in the 1H 2026, will transform Mannkind's Cardiometabolic Unit into a potential multi $ billion franchise that will hit the radar screen of top cardiometabolic disease companies like Biocrates Life Sciences AG, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Cardax, Inc., Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Kowa Company, Ltd, Allergan Inc., AstraZeneca Plc., Pfizer Inc., Merck & Co., Inc., and Sanofi SA, among others. Add to that Mannkind's Orphan Lung Disease Unit and Inhale Combination Drug Delivery Unit and its hard not to see how Mannkind isn't valued between $8 - $10 billion as a buyout target.

0 · Reply

JustAnotherJuggler Jan. 24 at 11:15 PM

$MNKD america. wakeUP!

2 · Reply

inv4future Jan. 24 at 6:35 PM

$MNKD On the FDA tracker for PDUFA it has MNKD for May 29th (Afrezza-in-Children-and-Adolescent)and also July 26th (sNDA-of-FUROSCIX). It does not show MNKD for Jan-April. https://www.fdatracker.com/fda-calendar/

1 · Reply

clan Jan. 24 at 4:46 PM

$MNKD Follow the pros.

0 · Reply

kevinmik Jan. 24 at 4:32 PM

$MNKD No doubt United Therapeutic will continue to contribute value to MNKD off of strong commercial sales that will inlcude IPF and eventually PPF, leaving what value will MNKD contribute on its own. In the 2H 2026, MNKD should have Afrezza & Furoscix expanded labels that turns the focus on MNKD driving its own value off of commercial sales for these products. Yes MNKD has other drugs in its pipeline pursuing clinical success, but the story line for MNKD value in the 2H 2026, will come from Tyvaso DPI, Afrezza & Furoscix. That said, Tyvaso DPI is in good hands with United Therapeutic who will no doubt drive huge commercial success, but what we will see from Afrezza & Furoscix commercially especially if MNKD goes solo for both. I don't think its best to wait and see how MNKD performs commercially for Afrezza & Furoscix and rather see MNKD leveraging Tyvaso Teton-1, Afrezza Pediatric, MNKD-201 & Furoscix Autoinjector 1H 2026 successes to pursue an M&A deal in the 2H 2026 or 1H 2027.

0 · Reply

grampslol Jan. 24 at 3:13 PM

$MNKD Behind the eight ball

0 · Reply

Outcomes Jan. 24 at 2:58 PM

$MNKD $UTHR $INKT $IRBX Very interesting comments about IPF....7:00 'This could be revolutionary'....... 'It's a great unmet need' Think.... immunocompromise....cancer, pulmonary fibrosis, diabetes, Covid.... 22:00 comments are JUST WOW! https://www.youtube.com/watch?v=FK76dUIRvh0

0 · Reply

clan Jan. 24 at 1:34 PM

$MNKD 100% owned and controlled by Mannkind. Could generated 1/2 BILLION in Revenues in 2028! (with LARGE-Marge type margins!) MNKD $50/sh by y.e. 2028. @MayorofMNKD $MRK $AMGN

1 · Reply

YolitheDolly Jan. 24 at 1:14 PM

$MNKD If you were an endo who refused to prescribe Afrezza for an adult would you prescribe it for a child?

4 · Reply

Market Cap	1.68B
Revenue (ttm)	285.50M
Net Income (ttm)	27.59M
EPS (ttm)	N/A
PE Ratio	59.10
Forward PE	67.16
Profit Margin	9.66%
Debt to Equity Ratio	-4.79

Volume	4,518,300
Avg Vol	3,479,036
Day's Range	N/A - N/A
Shares Out	307.07M
Stochastic %K	42%
Beta	0.81
Analysts	Strong Sell
Price Target	$9.61